App-Quantinova.ai

Fluid overload and acute kidney injury in children with tumor lysis syndrome.

Kayla Flood - Pediatric Academic Societies (PAS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute lymphoblastic leukemia

N/A

Case Series Non-Lipid Plaque Formation as the Mechanism for Ponatinib-Induced Vascular Toxicity Using Operator-Assisted Virtual Histology Optical Coherence Tomography

Moez Aziz - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute lymphoblastic leukemia

Ponatinib

RAPID DEVELOPMENT OF EOSINOPHILIC MYOCARDITIS AS THE INITIAL PRESENTATION OF CHRONIC MYELOID LEUKEMIA

Anis Adnani - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute lymphoblastic leukemia

N/A

PURGING OF MALIGNANT CELLS PRIOR TO SPERMATOGONIAL STEM CELL AUTO TRANSPLANTATION TO RESTORE FERTILITY

Omar Abdelaal - Society for Paediatric Urology (SPU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Genetic liability and late adverse musculoskeletal, metabolic and mental health effects in a cohort of survivors of childhood acute lymphoblastic leukemia – a PETALE study

Genevieve Nadeau - European Society for Paediatric Endocrinology (ESPE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

A Bloody Mess: A Rare Case of Spontaneous Hemothoraces from Chronic Myeloid Leukemia

E. Tope - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

A Fatal Case of Invasive Tracheobronchial Aspergillosis

M. Root - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

amphotericin B

Elevated Enhancer-Oncogene Contacts and Higher Oncogene Expression Levels By Recurrent CTCF inactivating Mutations in T Cell Acute Lymphoblastic Leukemia

Willem K. Smits - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Chromatin Content Capture Reveals Acute Leukaemia Oncogenic Vulnerability Point in Human B Cell Development

Reema Baskar - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Mapping the Glucocorticoid Gene Regulatory Network and Alterations That Contribute to Steroid Resistance in Childhood Acute Lymphoblastic Leukemia

Brennan P. Bergeron - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Glucocorticoid

Repurposing NAD Salvage Inhibitors for GCB Diffuse Large-B Cell Lymphoma

Claudio Scuoppo - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Nicotinamide

Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study

Sumit Gupta - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

The Clinical Outcomes and Genomic Landscapes of Acute Lymphoblastic Leukemia Patients with E2A-PBX1: A 10-Year Retrospective Study

Biqi Zhou - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Does Body Mass Index (BMI) during Maintenance Influence Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL)? Results from COG-AALL03N1

Aman Wadhwa - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

thioguanine

Epigenome-Wide Association Study of Acute Lymphoblastic Leukemia in Children with Down Syndrome

Shaobo Li - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol - a Graall Study

Corentin Orvain - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Sabina Chiaretti - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

A Phase 2 Study to Test the Feasibility, Safety and Efficacy of the Addition of Blinatumomab to the Interfant06 Backbone in Infants with Newly Diagnosed KMT2A-Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network

Inge M. van der Sluis - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Blinatumomab

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Nicola Goekbuget - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

PEG-asparaginase

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study

Patrice Chevallier - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

Filters

2187 Abstracts